Agilent Technologies (NYSE:A) Price Target Raised to $180.00

Agilent Technologies (NYSE:A) had its target price upped by Sanford C. Bernstein from $155.00 to $180.00 in a research report report published on Thursday,Benzinga reports. They currently have an outperform rating on the medical research company’s stock.

A number of other analysts have also issued reports on A. Barclays raised their price target on Agilent Technologies from $145.00 to $150.00 and gave the stock an “overweight” rating in a research note on Wednesday, June 24th. Jefferies Financial Group began coverage on shares of Agilent Technologies in a research note on Thursday, July 9th. They set a “hold” rating and a $135.00 price objective for the company. Morgan Stanley increased their price objective on shares of Agilent Technologies from $160.00 to $175.00 and gave the stock an “overweight” rating in a report on Wednesday, August 12th. HSBC decreased their target price on shares of Agilent Technologies from $180.00 to $165.00 and set a “buy” rating on the stock in a research report on Wednesday, June 3rd. Finally, Piper Sandler started coverage on shares of Agilent Technologies in a research report on Thursday, June 11th. They set a “neutral” rating and a $150.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Agilent Technologies presently has an average rating of “Moderate Buy” and an average price target of $170.33.

Agilent Technologies Trading Down 2.0%

Shares of A opened at $154.47 on Thursday. Agilent Technologies has a fifty-two week low of $108.35 and a fifty-two week high of $163.75. The company has a market capitalization of $43.63 billion, a PE ratio of 30.41, a price-to-earnings-growth ratio of 2.65 and a beta of 1.25. The stock has a fifty day moving average of $140.30 and a two-hundred day moving average of $127.04. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.62 and a current ratio of 2.05.

Agilent Technologies (NYSE:A) last posted its quarterly earnings data on Wednesday, August 26th. The medical research company reported $1.62 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.49 by $0.13. The business had revenue of $1.88 billion for the quarter, compared to analysts’ expectations of $1.84 billion. Agilent Technologies had a return on equity of 24.45% and a net margin of 19.53%.The business’s revenue was up 8.1% on a year-over-year basis. During the same quarter last year, the firm earned $1.37 earnings per share. Agilent Technologies has set its Q4 2026 guidance at 1.710-1.740 EPS and its FY 2026 guidance at 6.180-6.210 EPS. As a group, analysts forecast that Agilent Technologies will post 6.2 EPS for the current year.

Institutional Investors Weigh In On Agilent Technologies

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Corient Private Wealth LP raised its holdings in shares of Agilent Technologies by 8.5% in the 2nd quarter. Corient Private Wealth LP now owns 240,532 shares of the medical research company’s stock worth $31,952,000 after purchasing an additional 18,901 shares during the period. Amundi grew its holdings in shares of Agilent Technologies by 20.3% during the 2nd quarter. Amundi now owns 1,294,098 shares of the medical research company’s stock worth $171,891,000 after purchasing an additional 218,514 shares during the period. HighTower Advisors LLC grew its holdings in shares of Agilent Technologies by 3.3% during the 2nd quarter. HighTower Advisors LLC now owns 176,828 shares of the medical research company’s stock worth $23,488,000 after purchasing an additional 5,710 shares during the period. California State Teachers Retirement System increased its position in Agilent Technologies by 12,343.3% during the 2nd quarter. California State Teachers Retirement System now owns 54,577,058 shares of the medical research company’s stock worth $7,249,471,000 after purchasing an additional 54,138,451 shares in the last quarter. Finally, Wedmont Private Capital increased its position in Agilent Technologies by 10.8% during the 2nd quarter. Wedmont Private Capital now owns 5,599 shares of the medical research company’s stock worth $752,000 after purchasing an additional 547 shares in the last quarter.

Trending Headlines about Agilent Technologies

Here are the key news stories impacting Agilent Technologies this week:

• Positive Sentiment: Agilent reported fiscal Q3 earnings of $1.62 per share, above the $1.48-$1.49 analyst consensus, while revenue of approximately $1.88 billion also exceeded expectations. EPS increased from $1.37 a year earlier, supporting the view that profitability is improving. Agilent Technologies Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: Management raised its full-year guidance following the strong quarter. Commentary highlighted product momentum, a recovery in China, improving demand and expanding margins, all of which could support additional earnings growth. Agilent Technologies Lifts Outlook After Strong Quarter
• Positive Sentiment: Several major firms raised their price targets and maintained bullish ratings after the results. Targets now range from $175 to $190, with upgrades from JPMorgan, Citi, Barclays, Goldman Sachs, Bank of America, Stifel, TD Cowen, Bernstein and RBC. Analysts Raise Agilent Technologies Price Targets
• Neutral Sentiment: Despite the improved outlook, valuation remains relatively demanding: Agilent trades at roughly 30 times earnings, with a PEG ratio above 2.7. This leaves the stock sensitive to any slowdown in demand or disappointment in future guidance.

About Agilent Technologies

Agilent Technologies is a global provider of scientific instrumentation, consumables, software and services for laboratories across the life sciences, diagnostics and applied chemical markets. The company’s product portfolio includes analytical instruments such as liquid and gas chromatographs, mass spectrometers, spectroscopy systems, and laboratory automation solutions, together with reagents, supplies and informatics tools that support measurement, testing and data analysis workflows. Agilent also offers instrument maintenance, qualification and laboratory services designed to help customers improve productivity and comply with regulatory requirements.

Founded as a corporate spin-off from Hewlett‑Packard in 1999, Agilent has evolved through a combination of strategic restructuring and acquisitions to concentrate on life sciences, diagnostics and applied laboratories.